gsk

Patients treated with the drug had significantly less "off time," or waking time when their medication wore off and the motor symptoms of Parkinson's disease returned.

GlaxoSmithKline has a potential upside of 20.6% based on a current price of $41.93 and an average consensus analyst price target of $50.58.

Impax Laboratories and GlaxoSmithKline (NYSE:GSK) said that their extended-release experimental drug for Parkinson's disease met its main goal in a late-stage study. The clinical trial measured the effectiveness of the drug, IPX06

This is what's in the news for Friday, May 6th. the Wall Street Journal reports that Sen. Charles Schumer (D-NY) hasn't publicly taken a position on bids for the New York Stock Exchange (NYX) but behind the scenes he's now favorin

Chief Executive Andrew Witty said in a statement, "These first quarter results are in line with the expectation that I set out in February that GSK will make significant progress during 2011 to improve sales performance, enhance c

Shares of GlaxoSmithKline are trading up 1.65% at $42.41.

GlaxoSmithKline Plc (NYSE:GSK) reported a Q1 profit of $2.71 billion, beating the consensus estimate for $2.55 billion. Revenues were down 10.5% year-over-year to $10.90 billion, below the consensus estimate for $11.02 billion.

The intention to divest non-core consumer assets was first announced in the company's fourth quarter results Feb. 3, the WSJ reported.

GSK will start communicating with interested parties over the next few weeks, and hopes to divesting the products by late 2011, the report added.

Shares are up 0.62% to $40.75.

GlaxoSmithKline (GSK) announced that it has identified non-core OTC brands that it plans to divest to allow its consumer health care business to focus on a smaller portfolio of fast growing products and emerging markets, the Wall

Rumors are swirling that InterMune will receive a $60 per share takeover offer. Several major drug companies are looking at InterMune following the FDA approval of its lung disease drug Esbriet. Industry sources say GlaxoSmithKlin

The Norwegian group supplies Glaxo with the omega-3 heart medicine, which generated sales of GBP530 million last year for the U.K. drug maker, Dow Jones Newswires reports.

The deal, which is subject to review by the U.S. Federal Trade Commision, gives Apotex a license to enter the U.S.

GlaxoSmithKline plc (GSK) shares are up 0.89% to $38.48 at last look, after Pronova Biopharma, its Norwegian partner, reached a settlement with Canadian generics firm Apotex on U.S. patent rights over the drug, Lovaza.

Results of studies showed patients saw a reduction of 50% or more in seizure frequency compared to a placebo, when a dose of the medication was added to their current anti-epileptic drug therapy.

Pharmaceutical company GlaxoSmithKline PLC (NYSE:GSK) said Tuesday it and Valeant Pharmaceuticals International Inc. (NYSE:VRX) had been approved by the European Commission to begin marketing Trobalt, a treatment for partial onset